ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1375

Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin 33

Hyunho Lee1,2, Jun-ichi Kashiwakura3, Masahiko Yanagisawa1,2, Yuki Okamura1,2, Takao Ishii2, Masayuki Seki2, Shu Saito2, Yasuaki Tokuhashi2, Chisei Ra1 and Yoshimichi Okayama1, 1Allergy and Immunology Group, Nihon University School of Medicine, Tokyo, Japan, 2Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan, 3Laboratory for Allergic Disease, RIKEN Center for Integrateive Medical Sciences, Kanagawa, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: interleukins (IL), mast cells and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Recent studies suggest that human synovial mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). Circulating IgG isotype autoantibodies and synovial immune complexes are detected in RA patients. Therefore a plausible pathway for the activation of synovial MCs is through IgG receptors. However, it has not been well known whether IgG receptors are expressed on human synovial MCs. The purpose of this study was to investigate which IgG receptor(s) on synovial MCs are responsible for MC activation in response to immune complexes (IC), and to evaluate the effect of IL-33, which is believed to play an important role in RA, on IC-induced synovial MC activation.

Methods: We obtained synovial tissue specimens from RA patients and osteoarthritis (OA) patients after total knee replacement surgery. Synovial MCs were enzymatically dispersed. Cultured synovium-derived MCs were generated by culturing synovial cells with stem cell factor, and receptor expression was analyzed using fluorescence-activated cell sorting and immunohistochemical techniques. Mediators released from MCs were measured using enzyme immunoassays or enzymelinked immunosorbent assays.

Results: Primary synovial MCs and cultured synovium-derived MCs obtained from both RA patients and OA patients expressed Fcε receptor I (FcεRI), FcγRI, FcγRII and ST2 but not FcγRIII. Cultured synovium-derived MCs induced degranulation and the production of prostaglandin D2 and tumor necrosis factor α (TNF-α) through FcγRI. The activation through FcγRII caused histamine release from cultured MCs but not from primary MCs. Neutralizing anti-FcγRI monoclonal antibody and anti-FcγRII monoclonal antibody significantly inhibited histamine release induced by aggregated IgG. Aggregated IgG induced TNF-α production (~330 pg/ml/1×106 MCs) from cultured synovium-derived MCs. Although IL-33 did not enhance aggregated IgG-triggered histamine release, IL-33 (30 ng/mL) synergistically enhanced aggregated IgG-induced TNF-α production (~5.2 fold) in cultured synovium-derived MCs.

Conclusion: With Regard to the FcR expression profile, synovial MCs from RA patients and from OA patients were similar. FcγRI was responsible for producing abundant TNF-α from synovial MCs in response to aggregated IgG. Immune complexes may activate synovial MCs through FcγRI and FcγRII. In addition, IL-33 may exacerbate IC-mediated inflammation associated with RA by abundantly producing TNF-α from synovial MCs.


Disclosure:

H. Lee,
None;

J. I. Kashiwakura,
None;

M. Yanagisawa,
None;

Y. Okamura,
None;

T. Ishii,
None;

M. Seki,
None;

S. Saito,
None;

Y. Tokuhashi,
None;

C. Ra,
None;

Y. Okayama,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synergistic-enhancement-of-aggregated-igg-induced-tumor-necrosis-factor-%ce%b1-in-human-synovial-mast-cells-by-interleukin-33/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology